These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
282 related articles for article (PubMed ID: 24313827)
21. Probing the potential of apigenin liposomes in enhancing bacterial membrane perturbation and integrity loss. Banerjee K; Banerjee S; Das S; Mandal M J Colloid Interface Sci; 2015 Sep; 453():48-59. PubMed ID: 25965432 [TBL] [Abstract][Full Text] [Related]
22. Reducing Bacterial Infections and Biofilm Formation Using Nanoparticles and Nanostructured Antibacterial Surfaces. Mi G; Shi D; Wang M; Webster TJ Adv Healthc Mater; 2018 Jul; 7(13):e1800103. PubMed ID: 29790304 [TBL] [Abstract][Full Text] [Related]
23. Nano-therapeutics: A revolution in infection control in post antibiotic era. Zaidi S; Misba L; Khan AU Nanomedicine; 2017 Oct; 13(7):2281-2301. PubMed ID: 28673854 [TBL] [Abstract][Full Text] [Related]
24. The liposomal formulation of doxorubicin. Abraham SA; Waterhouse DN; Mayer LD; Cullis PR; Madden TD; Bally MB Methods Enzymol; 2005; 391():71-97. PubMed ID: 15721375 [TBL] [Abstract][Full Text] [Related]
25. Liposomal nanostructures for photosensitizer delivery. Jin CS; Zheng G Lasers Surg Med; 2011 Sep; 43(7):734-48. PubMed ID: 22057501 [TBL] [Abstract][Full Text] [Related]
26. Nanoparticulate platforms for targeting bone infections: meeting a major therapeutic challenge. Santos-Ferreira I; Bettencourt A; Almeida AJ Nanomedicine (Lond); 2015; 10(20):3131-45. PubMed ID: 26446355 [TBL] [Abstract][Full Text] [Related]
29. Liposomes and lipid carriers in the treatment of microbial infections. Bakker-Woudenberg IA; Lokerse AF Scand J Infect Dis Suppl; 1990; 74():34-41. PubMed ID: 2097717 [TBL] [Abstract][Full Text] [Related]
30. Current State of Nanomedicines in the Treatment of Topical Infectious Disorders. Thakur K; Sharma G; Singh B; Chhibber S; Katare OP Recent Pat Antiinfect Drug Discov; 2018; 13(2):127-150. PubMed ID: 29807522 [TBL] [Abstract][Full Text] [Related]
31. Drug delivery systems. 1. site-specific drug delivery using liposomes as carriers. Ranade VV J Clin Pharmacol; 1989 Aug; 29(8):685-94. PubMed ID: 2674208 [TBL] [Abstract][Full Text] [Related]
32. Liposomal systems as viable drug delivery technology for skin cancer sites with an outlook on lipid-based delivery vehicles and diagnostic imaging inputs for skin conditions'. Akhtar N; Khan RA Prog Lipid Res; 2016 Oct; 64():192-230. PubMed ID: 27697511 [TBL] [Abstract][Full Text] [Related]
33. [Progress of liposomes as antibiotic carriers]. Yang D; Xu Y; Li F; Liu H Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2012 Nov; 26(11):1387-90. PubMed ID: 23230678 [TBL] [Abstract][Full Text] [Related]
34. Recent Advances in Oral Nano-Antibiotics for Bacterial Infection Therapy. Wu ZL; Zhao J; Xu R Int J Nanomedicine; 2020; 15():9587-9610. PubMed ID: 33293809 [TBL] [Abstract][Full Text] [Related]
35. Nanoliposomal delivery systems of natural antibacterial compounds; properties, applications, and recent advances. Yousefi M; Andishmand H; Assadpour E; Barzegar A; Kharazmi MS; Jafari SM Crit Rev Food Sci Nutr; 2024; 64(19):6498-6511. PubMed ID: 36728840 [TBL] [Abstract][Full Text] [Related]
36. Investigation of the antibacterial activity and efflux pump inhibitory effect of co-loaded piperine and gentamicin nanoliposomes in methicillin-resistant Staphylococcus aureus. Khameneh B; Iranshahy M; Ghandadi M; Ghoochi Atashbeyk D; Fazly Bazzaz BS; Iranshahi M Drug Dev Ind Pharm; 2015 Jun; 41(6):989-94. PubMed ID: 24842547 [TBL] [Abstract][Full Text] [Related]
37. Nanocarriers for antibiotics: a promising solution to treat intracellular bacterial infections. Abed N; Couvreur P Int J Antimicrob Agents; 2014 Jun; 43(6):485-96. PubMed ID: 24721232 [TBL] [Abstract][Full Text] [Related]
38. Delivery of antibiotics with polymeric particles. Xiong MH; Bao Y; Yang XZ; Zhu YH; Wang J Adv Drug Deliv Rev; 2014 Nov; 78():63-76. PubMed ID: 24548540 [TBL] [Abstract][Full Text] [Related]
39. Antibacterial activity of liposomal gentamicin against Pseudomonas aeruginosa: a time-kill study. Rukholm G; Mugabe C; Azghani AO; Omri A Int J Antimicrob Agents; 2006 Mar; 27(3):247-52. PubMed ID: 16472992 [TBL] [Abstract][Full Text] [Related]
40. "Nanoantibiotics": a new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era. Huh AJ; Kwon YJ J Control Release; 2011 Dec; 156(2):128-45. PubMed ID: 21763369 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]